Search
for

    Research

    5 / 1000+ results

    Community Join

    3 / 1000+ results

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

       133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community Q1 2024 is done. And kintor is completely silent about GT20029.

       31 upvotes 2 years ago
      The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

    Learn

    2 / 801 results

      learn Osteopontin

      signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss